In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers

[1]  Koichiro Tamura,et al.  MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. , 2013, Molecular biology and evolution.

[2]  Andrew R. Jones,et al.  In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers , 2012, Genome Medicine.

[3]  M. Daly,et al.  Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. , 2011, Gastroenterology.

[4]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[5]  K. King,et al.  HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Andrew R. Jones,et al.  Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..

[7]  M. Pirmohamed,et al.  Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. , 2010, Journal of hepatology.

[8]  O. Lund,et al.  NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure , 2010, Immunome research.

[9]  S. Lewitzky,et al.  OC-035 Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a diagnostic test accuracy meta-analysis , 2010, Gut.

[10]  C. Day,et al.  Genetic association studies in drug-induced liver injury. , 2009, Seminars in liver disease.

[11]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[12]  O. Kantarci.  HLA-DRB1*0401 and HLA-DRB1*0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis , 2009 .

[13]  David Nolan,et al.  Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. , 2008, Immunity.

[14]  A Jawaid,et al.  Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis , 2008, The Pharmacogenomics Journal.

[15]  J. Lopes,et al.  Contemporary analysis of the influence of acute kidney injury (AKI) after myeloablative hematopoietic cell transplantation on long-term patient's survival , 2008, Bone Marrow Transplantation.

[16]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[17]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[18]  H. Takagi,et al.  Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study , 2008, The Pharmacogenomics Journal.

[19]  I. James,et al.  Cytokine Profiling in Abacavir Hypersensitivity Patients , 2008, Antiviral therapy.

[20]  O. Lund,et al.  NetMHCpan, a method for MHC class I binding prediction beyond humans , 2008, Immunogenetics.

[21]  I. James,et al.  Immune responses to abacavir in antigen-presenting cells from hypersensitive patients , 2007, AIDS.

[22]  G Thomson,et al.  PyPop update--a software pipeline for large-scale multilocus population genomics. , 2007, Tissue antigens.

[23]  H. Schultz.  From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI). , 2007, Autoimmunity reviews.

[24]  J. Uetrecht,et al.  Idiosyncratic drug reactions: current understanding. , 2007, Annual review of pharmacology and toxicology.

[25]  Pardis C Sabeti,et al.  A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC , 2006, Nature Genetics.

[26]  M. Pirmohamed,et al.  Activation of T cells by carbamazepine and carbamazepine metabolites. , 2006, The Journal of allergy and clinical immunology.

[27]  Jing Hua Zhao,et al.  Pedigree-drawing with R and graphviz , 2006, Bioinform..

[28]  J. Vielmetter,et al.  Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. , 2006, Clinical immunology.

[29]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M Setterholm,et al.  The HLA Dictionary 2004: a summary of HLA‐A, ‐B, ‐C, ‐DRB1/3/4/5 and ‐DQB1 alleles and their association with serologically defined HLA‐A, ‐B, ‐C, ‐DR and ‐DQ antigens , 2005, International journal of immunogenetics.

[31]  C. Moore,et al.  Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.

[32]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[33]  M Setterholm,et al.  Hematopoietic stem cell donor registry strategies for assigning search determinants and matching relationships , 2004, Bone Marrow Transplantation.

[34]  M. Pirmohamed,et al.  Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. , 2003, Molecular pharmacology.

[35]  Pradip Kumar Saha,et al.  Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. , 2002, American journal of respiratory and critical care medicine.

[36]  W. Pichler.  Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept , 2002, Current opinion in allergy and clinical immunology.

[37]  Simon Andrews,et al.  The PX domain: a new phosphoinositide-binding module. , 2002, Journal of cell science.

[38]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[39]  S G Marsh,et al.  The HLA dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. , 2001, Human immunology.

[40]  M. Pirmohamed,et al.  Metabolic activation in drug allergies. , 2001, Toxicology.

[41]  R. N. Macsween,et al.  Co-amoxiclav jaundice: clinical and histological features and HLA class II association , 2000, Gut.

[42]  L. Excoffier,et al.  A linkage disequilibrium map of the MHC region based on the analysis of 14 loci haplotypes in 50 French families , 2000, European Journal of Human Genetics.

[43]  C. Sempoux,et al.  HLA association of amoxicillin-clavulanate--induced hepatitis. , 1999, Gastroenterology.

[44]  C. Hewitt,et al.  Allergy to antibiotics: T‐cell recognition of amoxicillin is HLA‐DR restricted and does not require antigen processing , 1998, Allergy.

[45]  L. Excoffier,et al.  Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. , 1995, Molecular biology and evolution.

[46]  D. Goldfain,et al.  [Hepatitis caused by clometacin (Dupéran). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?]. , 1989, Gastroenterologie clinique et biologique.